A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma
Brief description of study
The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
Clinical Study Identifier: s15-01315
ClinicalTrials.gov Identifier: NCTs15-01315
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
